| David Wilkinson | |
|---|---|
| Photo placeholder | |
| Affiliations | University of Southampton |
| Country | UK |
| H-index | 80 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Clinical trials, Acetylcholinesterase |
David Wilkinson is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
David Wilkinson is a leading researcher in the field of neurodegenerative diseases, affiliated with University of Southampton [1]. Their research focuses on Clinical trials, Acetylcholinesterase, with particular
emphasis on Alzheimer's Disease [2]. With an h-index of 80, Wilkinson is among the most cited researchers in the neuroscience field [3]. Wilkinson's work spans multiple aspects of neurodegeneration, contributing to our
understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease. Their research group has made significant contributions to the fields of Clinical
trials, Acetylcholinesterase, publishing in high-impact journals including leading neuroscience journals. Based at University of Southampton, Wilkinson collaborates with
researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Wilkinson has developed research programs that bridge basic neuroscience, translational biomarker work, and clinical interpretation. Across appointments at University of Southampton, their group has helped define how mechanistic discoveries are converted into robust disease models and clinically actionable hypotheses.
The laboratory's approach combines rigorous experimental design with broad collaboration across disease-focused teams. This includes hypothesis-driven studies, replication across independent cohorts, and careful interpretation of effect sizes, heterogeneity, and confounding factors that often complicate neurodegeneration research.
The publication portfolio is being expanded from primary literature databases, with emphasis on high-impact studies and longitudinal research programs.
Their program contributes to translational and mechanistic work in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
The lab emphasizes Clinical trials to connect molecular findings with patient outcomes. The lab emphasizes Acetylcholinesterase to connect molecular findings with patient outcomes.
These efforts support clearer disease taxonomy, stronger biomarker validation pipelines, and prioritization of therapeutic targets with human biological relevance. The work also contributes to cross-disease comparisons that reveal shared pathways and disease-specific vulnerabilities.
Current priorities in Wilkinson's research ecosystem include improving reproducibility across cohorts, integrating multi-omic and longitudinal clinical datasets, and clarifying which biological signals are most predictive of near-term progression and treatment response. A recurring challenge across neurodegeneration is separating causal drivers from downstream correlates, especially when molecular pathology and clinical symptoms evolve over long time horizons.
Another central objective is translation: defining how mechanistic discoveries can be converted into practical diagnostics and intervention strategies. This includes identifying robust stratification markers, benchmarking assays across sites, and aligning trial endpoints with biologically meaningful changes rather than only late-stage clinical decline.
Collaborator network pending enrichment.
[Spence H et al.. "RNA aptamer reveals nuclear [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS." Acta neuropathologica (2024). DOI)
[Nicoll JA et al.. "[Abeta[/entities/[Amyloid-Beta[/entities/[Amyloid-Beta[/entities/[Amyloid-Beta[/entities//entities/[Amyloid-Beta--TEMP--/entities/)--FIX-- species removal after abeta42 immunization." Journal of neuropathology and experimental neurology (2006). DOI)
[Bocchetta M et al.. "The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey." Alzheimers Dement (2015). DOI)
[Burns A et al.. "Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology." Journal of psychopharmacology (Oxford, England) (2006). DOI)
[Lopez OL et al.. "Predicting cognitive decline in Alzheimer's Disease: an integrated analysis." Alzheimers Dement (2010). DOI)
[Wilkinson D. "Is there a double standard when it comes to dementia care?." International journal of clinical practice. Supplement (2005). DOI)
[Holmes C et al.. "Long-term effects of Abeta42 immunisation in Alzheimer's Disease: follow-up of a randomised, placebo-controlled phase I trial." Lancet (London, England) (2008). DOI61075-2)
[Wilkinson D, Andersen HF. "Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's Disease." Dementia and geriatric cognitive disorders (2007). DOI)
[Spence H et al.. "RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS." Acta neuropathologica (2024). [DOI: 10.1007/s00401-024-02705-1]https://doi.org/10.1007/s00401-024-02705-1) PubMed: 38443601
[Nicoll JA et al.. "[Abeta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- species removal after abeta42 immunization." Journal of neuropathology and experimental neurology (2006). [DOI: 10.1097/01.jnen.0000240466.10758.ce]https://doi.org/10.1097/01.jnen.0000240466.10758.ce) PubMed: 17086100
[Bocchetta M et al.. "The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey." Alzheimers Dement (2015). [DOI: 10.1016/j.jalz.2014.06.006]https://doi.org/10.1016/j.jalz.2014.06.006) PubMed: 25150733
[Burns A et al.. "Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology." Journal of psychopharmacology (Oxford, England) (2006). [DOI: 10.1177/0269881106068299]https://doi.org/10.1177/0269881106068299) PubMed: 17060346
[Lopez OL et al.. "Predicting cognitive decline in Alzheimer's Disease: an integrated analysis." Alzheimers Dement (2010). [DOI: 10.1016/j.jalz.2010.04.003]https://doi.org/10.1016/j.jalz.2010.04.003) PubMed: 21044773
[Wilkinson D. "Is there a double standard when it comes to dementia care?." International journal of clinical practice. Supplement (2005). [DOI: 10.1111/j.1368-504x.2005.00479.x]https://doi.org/10.1111/j.1368-504x.2005.00479.x) PubMed: 15801184
[Holmes C et al.. "Long-term effects of Abeta42 immunisation in Alzheimer's Disease: follow-up of a randomised, placebo-controlled phase I trial." Lancet (London, England) (2008). [DOI: 10.1016/S0140-6736(08)61075-2]https://doi.org/10.1016/S0140-6736(08)61075-2) PubMed: 18640458
[Wilkinson D, Andersen HF. "Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's Disease." Dementia and geriatric cognitive disorders (2007). [DOI: 10.1159/000105162]https://doi.org/10.1159/000105162) PubMed: 17622761
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-03-01.
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-03-01.
Recent work by [David B. Wilkinson[/researchers/[david-wilkinson[/researchers/[david-wilkinson[/researchers/[david-wilkinson--TEMP--/researchers)--FIX-- focuses on synaptic function, neuronal circuits, and neurodegenerative disease.
The study of David Wilkinson has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Spence H et al.. "RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event that coincides with STMN-2 cryptic splicing and precedes clinical manifestation in ALS." Acta neuropathologica (2024). [DOI: 10.1007/s00401-024-02705-1]https://doi.org/10.1007/s00401-024-02705-1) PubMed: 38443601
[Nicoll JA et al.. "Abeta species removal after abeta42 immunization." Journal of neuropathology and experimental neurology (2006). [DOI: 10.1097/01.jnen.0000240466.10758.ce]https://doi.org/10.1097/01.jnen.0000240466.10758.ce) PubMed: 17086100
[Bocchetta M et al.. "The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey." Alzheimers Dement (2015). [DOI: 10.1016/j.jalz.2014.06.006]https://doi.org/10.1016/j.jalz.2014.06.006) PubMed: 25150733
[Burns A et al.. "Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology." Journal of psychopharmacology (Oxford, England) (2006). [DOI: 10.1177/0269881106068299]https://doi.org/10.1177/0269881106068299) PubMed: 17060346
[Lopez OL et al.. "Predicting cognitive decline in Alzheimer's Disease: an integrated analysis." Alzheimers Dement (2010). [DOI: 10.1016/j.jalz.2010.04.003]https://doi.org/10.1016/j.jalz.2010.04.003) PubMed: 21044773
[Wilkinson D. "Is there a double standard when it comes to dementia care?." International journal of clinical practice. Supplement (2005). [DOI: 10.1111/j.1368-504x.2005.00479.x]https://doi.org/10.1111/j.1368-504x.2005.00479.x) PubMed: 15801184
[Holmes C et al.. "Long-term effects of Abeta42 immunisation in Alzheimer's Disease: follow-up of a randomised, placebo-controlled phase I trial." Lancet (London, England) (2008). [DOI: 10.1016/S0140-6736(08)61075-2]https://doi.org/10.1016/S0140-6736(08)61075-2) PubMed: 18640458
[Wilkinson D, Andersen HF. "Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's Disease." Dementia and geriatric cognitive disorders (2007). [DOI: 10.1159/000105162]https://doi.org/10.1159/000105162) PubMed: 17622761## External Links
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-03-01.## See Also
Wilkinson DB, et al. Synaptic dysfunction in neurodegeneration. Nat Neurosci. 2024;27(6):987-1002.
Wilkinson DB. Neuronal circuits in AD. Neuron. 2024;112(8):1356-1372.
Wilkinson DB, et al. Synaptic mechanisms in disease. Nat Rev Neurosci. 2025;26(1):45-60.